Analysis of the Gs/Mitogen-activated Protein Kinase Pathway in Mutant S49 Cells*

Yong Wan and Xin-Yun HuangDagger

From the Department of Physiology, Cornell University Medical College, New York, New York 10021

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Heterotrimeric G protein-coupled receptors can activate the mitogen-activated protein kinase (MAPK) cascade. Recent studies using pharmacological inhibitors or dominant-negative mutants of signaling molecules have advanced our understanding of the pathways from G protein-coupled receptors to MAPK. However, molecular genetic analysis of these pathways is inadequate in mammalian cells. Here, using the well characterized Gsalpha - and protein kinase A-deficient S49 mouse lymphoma cells, we provide the molecular genetic evidence that Gsalpha is responsible for transducing the beta -adrenergic receptor signal to MAPK in a protein kinase A-dependent pathway involving Rap1 and Raf (but not Ras) molecules.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

G proteins serve their physiological roles by transducing signals from a broad class of cell-surface receptors to specific effector proteins (1-4). A variety of intracellular signal transduction pathways are regulated by G proteins, including the mitogen-activated protein kinase (MAPK)1 pathway (5). Although the activation mechanism of the MAPK cascade by receptors with intrinsic tyrosine kinase activity has been well studied, the route from G proteins to the MAPK cascade in mammalian cells is less understood (6, 7).

Recent studies in cultured cell lines with pharmacological inhibitors and dominant-negative mutants of certain signaling molecules have revealed the participation of some molecular components in the regulation of MAPK by G protein-coupled receptors (for review, see Ref. 5). Although the detailed biochemical steps are far from clear, these studies have shown that G protein-coupled receptors use pathways very similar to those utilized by receptor tyrosine kinases to activate the prototype Raf/MEK/MAPK cascade. Gq- and Gi-coupled receptors transmit the signals to MAPK through a pathway involving tyrosine kinase, adapter proteins Shc and Grb2, guanine nucleotide exchange factor Sos, Ras, and Raf in most cases (for review, see Ref. 5). Phosphatidylinositol 3-kinase has been implicated to act upstream of tyrosine kinases in the Gi/MAPK pathway in some cells (8-12).

For receptors coupled to Gs, overexpressing Gbeta gamma or Gsalpha subunits in COS-7 cells has shown that whereas Gbeta gamma subunits have the capacity to stimulate MAPK, the ability of Gsalpha to stimulate MAPK is controversial (13, 14). It is also unclear if cAMP and protein kinase A (PKA) participate in the Gs-coupled receptor/MAPK pathway. Whereas one group reported that cAMP, forskolin, and Gs-coupled receptors can stimulate MAPK in COS-7 cells (13), another reported that cAMP and PKA do not mediate activation of MAPK by Gs-coupled receptors in COS-7 cells (14). It was proposed that the Gs-coupled beta -adrenergic receptor used the Gbeta gamma subunit to activate the MAPK pathway through Ras and used the Gsalpha subunit to inhibit MAPK activation through cAMP and PKA (14). These contradictory results regarding whether the alpha -subunit or the beta gamma -subunits of Gs protein mediate the receptor stimulation of MAPK and whether PKA is involved in the Gs/MAPK pathway in mammalian cells prompted us to address this question genetically. For the most part, signaling by heterotrimeric G proteins has not been studied genetically in mammalian cells.

S49 mouse lymphoma cells have played an important historical role in G protein research (15). A variant of S49 cells lacking Gsalpha was instrumental in defining the function of and characterizing Gsalpha (15). Elevation of intracellular cAMP levels results in growth arrest in the G1 phase of the cell cycle and later (after several days) in cell death (16, 17). Mutants have been selected that are resistant to cytolysis. These mutants include cyc- (which lacks Gsalpha ) (18), UNC (which has a mutation of arginine at position 372 of Gsalpha and thus uncouples the interaction of Gsalpha with the receptors) (19), and kin- (which lacks protein kinase A activity) (20).

These Gsalpha and PKA mutant S49 cells should be very useful in a molecular genetic study to understand the role of Gsalpha and PKA in the beta -adrenergic receptor/MAPK signaling system. In this study, using these mutant S49 cells, we demonstrate that Gsalpha transduces the beta -adrenergic receptor signal to MAPK in a protein kinase A-dependent pathway involving Rap1 and Raf (but not Ras) molecules.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

S49 Mouse Lymphoma Cells-- S49 mouse lymphoma T cells were obtained from the Cell Culture Facility at the University of California at San Francisco and were grown in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated horse serum as described (16, 17, 21). Transient transfection was done with 2 µg of plasmid DNA and LipofectAMINE (Life Technologies, Inc.) in six-well culture plates as described previously (22-25). Transfection efficiency was ~20%.

Immunoprecipitation and Immunoblot Analysis-- S49 whole cell extracts were prepared as follows. Cells were harvested from 10-cm plates and washed twice with cold phosphate-buffered saline, and pellets were resuspended in 0.8 m1 of extraction buffer (150 mM NaCl, 10 mM Tris, pH 7.4, l mM EDTA, l mM EGTA, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 0.5% Nonidet P-40, 0.2 mM phenylmethylsulfonyl fluoride, 0.2 mM sodium orthovanadate, 0.02 mg/m1 tosylphenylalanyl chloromethyl ketone, and 0.03 mg/m1 leupeptin). Resuspended pellets were passed five times through a 26-gauge needle and centrifuged at 5000 rpm for 5 min at 4 °C to remove insoluble material, and the supernatant was saved as the whole cell extract. For immunoprecipitation, 10 µl of protein G-agarose was added to the whole cell lysate to preclear. Then, 5 µl of primary antibody was added and continuously incubated at 4 °C for 30 min. After another 2-h incubation with 30 µl of protein G-agarose beads, the immunocomplex was washed three times with extraction buffer and three times with wash buffer (10 mM Tris, pH 7.4, and 1 mM EDTA). The immunocomplex was then subjected to SDS-polyacrylamide gel electrophoresis. Western blotting with anti-ERK-1, anti-Gsalpha , anti-Gbeta , and anti-Gialpha was done as described (22-25). Anti-G protein antibodies were from Santa Cruz Biotechnology. Membrane filters were incubated in 1× Tris-buffered saline/5% milk for 1 h and then incubated in primary antibody for 2 h at room temperature. Blots were washed three times with Tris-buffered saline/Tween-20 and one time with Tris-buffered saline and then incubated with secondary antibody for 2 h at room temperature. Blots were washed again, and signal was detected with ECL (NEN Life Science Products).

MAPK Assay-- For treatments, cells were stimulated with 100 µM isoproterenol or 1 µM somatostatin for 5 min. This brief treatment (5 min) with isoproterenol did not cause cell death. Whole cell lysate was prepared, and immunocomplex MAPK assay was performed as described previously using myelin basic protein (10 µg) as substrate (23, 24). ERK-1 immunoprecipitation was done with a monoclonal antibody to ERK-1 (Transduction Laboratories). Kinase assay buffer contained 30 mM Tris-HCl, pH 8, 20 mM MgC12, 2 mM MnC12, and 10 µM ATP. The mixture was preincubated for 3 min before 10 µCi of [gamma -32P]ATP was added. After 10 min at 30 °C, samples were separated by 12% SDS-polyacrylamide gel electrophoresis. Gels were transferred to nitrocellulose membrane filters and exposed for autoradiography. Quantitation was performed using a Molecular Dynamics PhosphorImager.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Gsalpha Is Required for Transmitting the beta -Adrenergic Receptor Signal to MAPK-- In wild-type S49 mouse lymphoma cells, the agonist isoproterenol activates the endogenous Gs-coupled beta -adrenergic receptor, leading to the stimulation of MAPK activity (Fig. 1A). Isoproterenol-induced increase in MAPK activity was not sensitive to pertussis toxin and could be blocked by the beta -adrenergic receptor-specific antagonist propranolol (data not shown). To genetically determine whether Gsalpha or Gbeta gamma subunits transduce the receptor signal to MAPK, we have taken advantage of the availability of mutant S49 cells that have genetic defects in beta -receptor signaling.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 1.   Stimulation of MAPK by Gs- and Gi-coupled receptors in wild-type and Gsalpha mutant S49 cells. A, in wild-type (WT) S49 cells, the agonist isoproterenol (ISO) activated the endogenous Gs-coupled beta -adrenergic receptor, leading to the stimulation of MAPK activity. Cells were treated for 5 min with isoproterenol (100 µM) or somatostatin (SOM; 1 µM). MAPK activity was assayed with myelin basic protein (MBP) as substrate. In cyc- cells, stimulation of the beta -adrenergic receptor failed to increase the activity of MAPK, although the stimulation of MAPK by the endogenous Gi-coupled somatostatin receptor was normal. The isoproterenol effect could be blocked by the beta -receptor antagonist propranolol (data not shown). B, in UNC cells, stimulation of the beta -adrenergic receptor failed to increase the activity of MAPK, although the stimulation of MAPK by the Gi-coupled somatostatin receptor was normal. C, shown are the results of Western blot analysis of the expression of Gsalpha , Gbeta , and Gialpha in wild-type and mutant S49 cells. D, shown are the results from the quantification of Gs- and Gi-coupled receptor-stimulated MAPK activity. Data represent the means ± S.D. of four to six experiments.

In cyc- S49 cells that lack Gsalpha proteins (a null mutant), stimulation of the beta -adrenergic receptor failed to activate adenylyl cyclase or to increase intracellular cAMP (18). As shown in Fig. 1 (A and D), in these Gsalpha -deficient cells, stimulation of the beta -adrenergic receptor failed to increase the activity of MAPK, although the stimulation of MAPK by the endogenous Gi-coupled somatostatin receptor was normal. As expected, the Gi-mediated somatostatin-induced increase in MAPK activity was blocked by pertussis toxin (data not shown). This result indicates that Gsalpha is positively required for transmitting the beta -adrenergic receptor signal to MAPK.

To further confirm the necessity of Gsalpha for this signal transduction pathway, we tested another allele of the Gsalpha mutant, the UNC S49 cells. The UNC mutant of Gsalpha has a single amino acid change at position 372 (from arginine to proline), six residues from the carboxyl terminus (19, 26). This mutant Gsalpha fails to couple to the beta -adrenergic receptor. Thus, the beta -adrenergic receptor signal is unable to be delivered to downstream targets in vivo. As shown in Fig. 1 (B and D), in UNC mutant S49 cells, stimulation of the beta -adrenergic receptor failed to stimulate MAPK activity. Again, stimulation of MAPK by the endogenous Gi-coupled somatostatin receptor was normal. These data reaffirm that Gsalpha is necessary for beta -adrenergic receptor/MAPK signaling. The inability of cyc- and UNC mutant S49 cells to respond to isoproterenol in stimulating MAPK was not due to gross abnormality of G protein expression in these mutants since we found that expression of Gsalpha , Gbeta , and Gialpha proteins in all cell lines was similar, except that Gsalpha was missing in cyc- cells (Fig. 1C).

Gsalpha Is the Signal Transducer in the beta -Adrenergic Receptor/MAPK Pathway-- The requirement for Gsalpha may be due to its signaling role or to its requirement in maintaining the structural integrity of trimeric G proteins or both. To distinguish between the signaling versus structural role, we introduced into cyc- cells (a null Gsalpha mutant background) a Gsalpha mutant that still complexes with the Gbeta gamma subunit and is still able to couple to the beta -adrenergic receptor (that is, the structural role is still fulfilled), but is unable to stimulate its downstream target adenylyl cyclase (that is, the signaling role is impaired). If such a mutant is unable to rescue the cyc- mutant response to beta -adrenergic receptor stimulation of MAPK, then Gsalpha is very likely the signal transducer. If such a mutant is able to rescue the cyc- response to beta -adrenergic receptor stimulation of MAPK, Gsalpha is probably needed for structural integrity. Therefore, we tested two Gsalpha mutants with amino acid changes in the effector contact region of Gsalpha , previously described to be defective in stimulating adenylyl cyclase, but still interacting with Gbeta gamma and the beta -adrenergic receptor (27, 28). As shown in Fig. 2, wild-type Gsalpha rescues the cyc- cell response to beta -adrenergic stimulation of MAPK, whereas neither of the two mutants could rescue the response. Furthermore, expression of a constitutively activated Gsalpha mutant (alpha sQ227L, with Gln227 changed to Leu) (29) leads to stimulation of MAPK, indicating that Gsalpha is not only required but also sufficient to activate the MAPK pathway. Thus, we conclude that Gsalpha is the signal transducer in the beta -adrenergic receptor/MAPK pathway.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 2.   Rescue of the stimulation of MAPK by Gs-coupled receptors in cyc- cells by mutant Gsalpha . A, transfection of constitutively active Gsalpha (alpha sQ227L) leads to the activation of MAPK (lane 1). Transfection of Gsalpha mutants (alpha s89 (lanes 4 and 5; alpha s389 (lanes 6 and 7)) failed to rescue the activation of MAPK in response to isoproterenol (ISO) stimulation. In mutant alpha s89, Leu268 and Arg269 were changed to phenylalanine and threonine, respectively. In mutant alpha s389, Trp263, Leu268, and Arg269 were changed to cysteine, phenylalanine, and threonine, respectively. These mutants have a markedly reduced ability to activate adenylyl cyclase (27). Transfection of wild-type (WT) Gsalpha (lanes 8 and 9) restored the response of MAPK to beta -receptor stimulation. B, quantification of receptor-stimulated MAPK activity. The values shown represent the means ± S.D. of four experiments.

PKA Is Required for Transmitting the beta -Adrenergic Receptor Signal to MAPK-- Binding of isoproterenol to the beta -adrenergic receptor results in the activation of Gsalpha , leading to stimulation of adenylyl cyclase and elevation of the intracellular levels of cAMP. Most cAMP-mediated intracellular responses are mediated through protein kinase A in mammalian cells (30). As shown in Fig. 3, stimulation of MAPK by the beta -adrenergic receptor is blocked in kin- mutant S49 cells that lack protein kinase A activity (20), whereas stimulation of MAPK by the Gi-coupled somatostatin receptor is normal in kin- cells. This result further demonstrates that the Gsalpha /adenylyl cyclase/cAMP/protein kinase A cascade links the beta -adrenergic receptor to MAPK in S49 mouse lymphoma cells.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 3.   Stimulation of MAPK by Gs-coupled and Gi-coupled receptors in kin- S49 cells. A, in kin- cells, stimulation of the beta -adrenergic receptor failed to increase the activity of MAPK, whereas the stimulation of MAPK by the Gi-coupled somatostatin (SOM) receptor was normal. B, shown are the results from the quantification of Gs- and Gi-coupled receptor-stimulated MAPK activity. Data represent the means ± S.D. of four experiments. WT, wild-type S49 cells; ISO, isoproterenol; MBP, myelin basic protein.

Downstream Components of the PKA/MAPK Pathway in S49 Cells-- Activation of MAPK by PKA in some cells has been proposed to act through a Ras-independent but B-Raf- and Rap1-dependent signaling pathway (31). To examine the role of Ras, Raf, and Rap1 in the PKA/MAPK pathway in S49 cells, we tested the effects of dominant-negative mutants of Ras, Raf, and Rap1 (Fig. 4). Expression of a dominant-negative Ras mutant (RasN17) (32) in S49 cells had no effect on the stimulation of MAPK by Gs-coupled beta -receptors (Fig. 4A), whereas it inhibited the MAPK stimulation by Gi-coupled somatostatin receptors (Fig. 4B). Transfection of a dominant-negative Raf mutant (a truncated Raf mutant with the conserved region 1, which interferes with the activation of endogenous Raf including B-Raf) (33-36) into S49 cells blocked the MAPK stimulation by both Gs- and Gi-coupled receptors (Fig. 4). While there was no effect on the stimulation of MAPK by the Gi-coupled somatostatin receptor, transfection of a dominant-negative Rap1 mutant (Rap1N17) (31) blocked the MAPK stimulation by the Gs-coupled beta -receptor (Fig. 4C). These data suggest that in S49 cells, as in some other mammalian cells, the PKA/MAPK pathway requires Rap1 and Raf, but not Ras (31, 37).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 4.   Effects of dominant-negative mutants of Ras, Raf, and Rap1 on the stimulation of MAPK by Gs- and Gi-coupled receptors in S49 cells. A, whereas a dominant-negative Ras mutant (dnRas) has no effect on the stimulation of MAPK by Gs-coupled receptors, a dominant-negative Raf mutant (dnRaf) inhibits the MAPK activation by Gs-coupled receptors. B, both a dominant-negative Ras mutant and a dominant-negative Raf mutant inhibit the MAPK stimulation by Gi-coupled receptors. C, a dominant-negative Rap1 mutant (dnRap1) blocks the stimulation of MAPK by Gs-coupled receptors, but has no effect on the stimulation by Gi-coupled receptors. D, quantification of receptor-stimulated MAPK activity. The values shown represent the means ± S.D. of four experiments. WT, wild-type S49 cells; ISO, isoproterenol; MBP, myelin basic protein; SOM, somatostatin.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In summary, using various mutant S49 mouse lymphoma cells, we have provided the first genetic evidence for Gsalpha and protein kinase A transducing the beta -adrenergic receptor signal to MAPK. In cyc- mutant S49 cells that lack Gsalpha proteins, stimulation of the beta -adrenergic receptor failed to activate MAPK. In UNC mutant S49 cells that Gsalpha is unable to couple to the beta -adrenergic receptor, MAPK could not be stimulated by the beta -receptor. Two Gsalpha mutants that can complex with the Gbeta gamma subunit and beta -receptor, but are unable to stimulate adenylyl cyclase, failed to rescue the cyc- mutant response to beta -receptor stimulation of MAPK. Wild-type Gsalpha rescued the cyc- cell response. Furthermore, in kin- mutant S49 cells that lack protein kinase A activity, stimulation of MAPK by the beta -receptor was blocked. Moreover, dominant-negative mutants of Rap1 or Raf, but not Ras, suppressed the beta -receptor-induced MAPK stimulation. These data collectively demonstrate that the Gs-coupled adrenergic receptor uses Gsalpha , transducing the signal to a PKA-, Rap1-, and Raf-dependent, but Ras-independent, pathway leading to MAPK activation in S49 mouse lymphoma cells.

Previously, Faure et al. (13) have shown that overexpressing Gbeta gamma or constitutively activated Gsalpha could lead to activation of MAPK and that cAMP, forskolin, and Gs-coupled receptors could stimulate MAPK in COS-7 cells. On the other hand, Crespo et al. (14) reported that only overexpression of Gbeta gamma subunits, but not the activated Gsalpha subunit, could increase MAPK activity in COS-7 cells. It was proposed that in COS-7 cells, whereas Gbeta gamma transduces a positive signal to increase MAPK activity, Gsalpha , through protein kinase A, inhibits the MAPK stimulation (14). The reason for this discrepancy is not clear. The suggestion that Gbeta gamma mediates the beta -adrenergic receptor signal to MAPK is based on two types of experiments (14). One is that, as mentioned above, overexpression of Gbeta gamma could lead to increased MAPK activity. Another is that overexpression of a Gbeta gamma -binding fragment from the beta -adrenergic receptor kinase protein or Gtalpha could attenuate the stimulation of MAPK by beta -adrenergic receptors.

We were unable to perform a genetic analysis of the role of Gbeta gamma subunits due to the lack of null mutants of Gbeta or Ggamma subunits in S49 cells. Gbeta gamma is likely required in a structural role for the integrity of G protein function, but is unlikely to play a major signaling role for the following reasons. First, in cyc- mutant cells, the basal activity of MAPK is similar to that in wild-type cells. If Gbeta gamma is the major signal transducer, as in Saccharomyces cerevisiae, then in cyc- cells, MAPK could be constitutively active, as in Galpha null mutant cells in S. cerevisiae (38, 39). Second, two mutant Gsalpha (alpha s89 and alpha s389) subunits did not rescue the cyc- cell response despite being able to release Gbeta gamma upon receptor stimulation. Third, in S49 cells, the isoforms of adenylyl cyclases can be stimulated by Gsalpha , but not by Gbeta gamma or calcium/calmodulin (40). These data suggest that if Gbeta gamma is needed, it is for structural reasons only, not for activating downstream targets. Therefore, in S49 mouse lymphoma cells, Gsalpha , not Gbeta gamma , transduces the receptor signal to MAPK.

In the fission yeast Schizosaccharomyces pombe, the alpha -subunit of G protein carries the signal to the MAPK pathway (41). In the budding yeast S. cerevisiae, the beta gamma -subunit of G protein couples the receptor to the MAPK cascade (38, 39). Given that the alpha -subunit of Gs transduces Gs-coupled receptor signal to MAPK in S49 cells and that the beta gamma -subunit of Gi likely conveys the message from Gi-coupled receptors to MAPK (13, 42, 43), these different usages of the alpha  and beta gamma subunits might be reminiscent of S. pombe versus S. cerevisiae MAPK signaling pathways. Thus, mammalian cells have both yeast pathways that are utilized by different families of G proteins.

The cAMP and protein kinase A effect on the MAPK pathway depends on cell type: in some cells, they are stimulatory to the MAPK pathway, whereas in other cells, they are inhibitory (44, 45). A recent study has determined that these stimulatory or inhibitory effects are dictated by the expression of B-Raf (31). Protein kinase A directly activates the small G protein Rap1, which in turn, selectively and directly activates B-Raf, leading to the activation of MAPK. We found that B-Raf is expressed in S49 cells and that isoproterenol could stimulate B-Raf activity in S49 cells. Also, we have examined the activation of MEK, an upstream activator of MAPK, and obtained results similar to those for MAPK activation. Thus, we propose the activation sequence as beta -adrenergic receptor/Gsalpha /adenylyl cyclase/cAMP/PKA/Rap1/B-Raf/MEK/MAPK. This Gsalpha /MAPK pathway represents the first complete biochemical pathway for G protein/MAPK signaling.

    ACKNOWLEDGEMENTS

We thank Drs. T. Kozasa, A. Gilman, and P. Stork for providing plasmids. We are grateful to Drs. R. Iyengar, L. Levin, T. Maack, and the members of our laboratory for reading the manuscript.

    FOOTNOTES

* This work was supported by grants from NIH, the National Science Foundation, and the American Heart Association.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Beatrice F. Parvin Investigator of the American Heart Association, New York City Affiliate. To whom correspondence should be addressed: Dept. of Physiology, Cornell University Medical College, 1300 York Ave., New York, NY 10021. Tel.: 212-746-6362; Fax: 212-746-8690; E-mail: xyhuang{at}mail.med.cornell.edu.

1 The abbreviations used are: MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase/extracellular signal-regulated protein kinase kinase; PKA, protein kinase A.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Gilman, A. (1987) Annu. Rev. Biochem. 56, 615-649[CrossRef][Medline] [Order article via Infotrieve]
  2. Bourne, H. R., Sanders, D. A., and McCormick, F. (1991) Nature 349, 117-127[CrossRef][Medline] [Order article via Infotrieve]
  3. Simon, M. I., Strathmann, M. P., and Gautam, N. (1991) Science 252, 802-808[Medline] [Order article via Infotrieve]
  4. Clapham, D. E., and Neer, E. J. (1993) Nature 365, 403-406[CrossRef][Medline] [Order article via Infotrieve]
  5. Post, G. R., and Brown, J. H. (1996) FASEB J. 10, 741-749[Abstract/Free Full Text]
  6. Seger, R., and Krebs, E. G. (1995) FASEB J. 9, 726-735[Abstract/Free Full Text]
  7. Herskowitz, I. (1995) Cell 80, 187-197[Medline] [Order article via Infotrieve]
  8. Ferby, I. M., Waga, I., Sakanaka, C., Kume, K., and Shimizu, T. (1994) J. Biol. Chem. 269, 30485-30488[Abstract/Free Full Text]
  9. Pace, A. M., Faure, M., and Bourne, H. R. (1995) Mol. Biol. Cell 6, 1685-1695[Abstract]
  10. Hawes, B. E., Luttrell, L. M., van Biesen, T., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 12133-12136[Abstract/Free Full Text]
  11. Cowen, D. S., Sowers, R. S., and Manning, D. R. (1996) J. Biol. Chem. 271, 22297-22300[Abstract/Free Full Text]
  12. Lopez-Ilasaca, M., Crespo, P., Pellici, P. G., Gutkind, J. S., and Wetzker, R. (1997) Science 275, 394-397[Abstract/Free Full Text]
  13. Faure, M., Voyno-Yasenetskaya, T. A., and Bourne, H. R. (1994) J. Biol. Chem. 269, 7851-7854[Abstract/Free Full Text]
  14. Crespo, P., Cachero, T. G., Xu, N., and Gutkind, J. S. (1995) J. Biol. Chem. 270, 25259-25265[Abstract/Free Full Text]
  15. Gilman, A. G. (1995) Biosci. Rep. 15, 65-97[Medline] [Order article via Infotrieve]
  16. Coffino, P., Bourne, H. R., and Tomkins, G. M. (1975) J. Cell. Physiol. 85, 603-610[Medline] [Order article via Infotrieve]
  17. Bourne, H. R., Coffino, P., and Tomkins, G. M. (1975) J. Cell. Physiol. 85, 611-620[Medline] [Order article via Infotrieve]
  18. Bourne, H. R., Coffino, P., and Tomkins, G. M. (1975) Science 187, 750-752[Medline] [Order article via Infotrieve]
  19. Haga, T., Ross, E. M., Anderson, H. J., and Gilma, A. G. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 2016-2020[Abstract]
  20. Insel, P. A., Bourne, H. R., Coffino, P., and Tomkins, G. M. (1975) Science 190, 896-897[Medline] [Order article via Infotrieve]
  21. Hadcock, J. R., Ros, M., and Malbon, C. C. (1989) J. Biol. Chem. 264, 13956-13961[Abstract/Free Full Text]
  22. Langhans-Rajasekaran, S. A., Wan, Y., and Huang, X.-Y. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8601-8605[Abstract]
  23. Wan, Y., Kurosaki, T., and Huang, X.-Y. (1996) Nature 380, 541-544[CrossRef][Medline] [Order article via Infotrieve]
  24. Wan, Y., Bence, K., Hata, A., Kurosaki, T., Veillette, A., and Huang, X.-Y. (1997) J. Biol. Chem. 272, 17209-17215[Abstract/Free Full Text]
  25. Bence, K., Ma, W., Kozasa, T., and Huang, X.-Y. (1997) Nature 389, 296-299[CrossRef][Medline] [Order article via Infotrieve]
  26. Sullivan, K. A., Miller, R. T., Master, S. B., Beiderman, B., Heideman, W., and Bourne, H. R. (1987) Nature 330, 758-760[CrossRef][Medline] [Order article via Infotrieve]
  27. Itoh, H., and Gilman, A. G. (1991) J. Biol. Chem. 266, 16226-16231[Abstract/Free Full Text]
  28. Berlot, C. H., and Bourne, H. R. (1992) Cell 68, 911-922[Medline] [Order article via Infotrieve]
  29. Graziano, M. P., and Gilman, A. G. (1989) J. Biol. Chem. 264, 15475-15482[Abstract/Free Full Text]
  30. Walsh, D. A., and Van Patten, S. M. (1994) FASEB J. 8, 1227-1236[Abstract/Free Full Text]
  31. Vossler, M. R., Yao, H., York, R. D., Pan, M.-G., Rim, C. S., and Stork, P. J. S. (1997) Cell 89, 73-82[Medline] [Order article via Infotrieve]
  32. Stacy, D. W., Feig, L. A., and Gibbs, J. B. (1991) Mol. Cell. Biol. 11, 4053-4064[Medline] [Order article via Infotrieve]
  33. Kolch, W., Heidecker, G., Lloyd, P., and Rapp, U. R. (1991) Nature 349, 426-428[CrossRef][Medline] [Order article via Infotrieve]
  34. Cai, H., Erhardt, P., Troppmair, J., Diaz-Meco, M. T., Sithanandam, G., Rapp, U. R., Moscat, J., and Cooper, G. M. (1993) Mol. Cell. Biol. 13, 7645-7651[Abstract]
  35. Shibuya, E. K., Morris, J., Rapp, U. R., and Ruderman, J. V. (1996) Cell Growth Differ. 7, 235-241[Abstract]
  36. Cosgaya, J. M., and Aranda, A. (1996) Oncogene 12, 2651-2660[Medline] [Order article via Infotrieve]
  37. Verheijen, M. H. G., and Defize, L. H. K. (1997) J. Biol. Chem. 272, 3423-3429[Abstract/Free Full Text]
  38. Dietzel, C., and Kurjan, J. (1987) Cell 50, 1001-1010[Medline] [Order article via Infotrieve]
  39. Miyajima, I., Nakafuku, M., Nakayama, N., Brenner, C., Miyajima, A., Kaibuchi, K., Arai, K., Kaziro, Y., and Matsumoto, K. (1987) Cell 50, 1011-1019[Medline] [Order article via Infotrieve]
  40. Tang, W.-J., and Gilman, A. G. (1991) Science 254, 1500-1503[Medline] [Order article via Infotrieve]
  41. Obara, T., Nakafuku, M., Yamamoto, M., and Kaziro, Y. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 5877-5881[Abstract]
  42. Crespo, P., Xu, N., Simonds, W. F., and Gutkind, J. S. (1994) Nature 369, 418-420[CrossRef][Medline] [Order article via Infotrieve]
  43. Koch, W. J., Hawes, B. E., Allen, L. F., and Lefkowitz, R. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12706-12710[Abstract/Free Full Text]
  44. Faure, M., and Bourne, H. R. (1995) Mol. Biol. Cell 6, 1025-1035[Abstract]
  45. Burgering, B. M. T., and Bos, J. L. (1995) Trends Biol. Sci. 20, 18-22 [CrossRef]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.